Australia is anticipating the introduction of Retatrutide, a groundbreaking medication from Novo Nordisk. This combined-action drug, targeting both GLP-1 and GIP receptors, has shown impressive performance in clinical https://mediajx.com/story365855/this-new-drug-retatrutide-australia-a-potential-advancement-for-obesity-treatment